Aurinia Pharmaceuticals Inc. With a focus on lupus nephritis, they strive to develop breakthrough treatments that set new standards in patient care. Their mission and vision revolve around providing patients with the opportunity to thrive, backed by their strong values.

Aurinia's remarkable journey began with their founders' unwavering determination to find solutions for autoimmune diseases. By assembling a team of experts in drug research, development, and commercialization, they partnered with like-minded organizations to expedite the delivery of life-changing therapies to as many patients as possible. Notable milestones include their FDA Fast Track designation for voclosporin, the approval of LUPKYNIS® by the FDA, and the European Union's approval of LUPKYNIS in combination with mycophenolate mofetil for the treatment of lupus nephritis.

Aurinia is committed to changing the trajectory of autoimmune diseases and ensuring health equity for all patients. They value collaboration and have strategic partnerships with global leaders in academia, research, and industry. With recognition from the healthcare community, Aurinia continues to drive innovation and make a positive impact in the field of autoimmune disease treatment.

To join Aurinia's mission and contribute to their groundbreaking work, you can contact their Business Development, Investor Relations, Clinical Trials, or Medical Information teams